Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison
Abstract
Dual antiplatelet therapy with Aspirin and Clopidogrel has been considered as a cornerstone therapy after acute coronary syndrome (ACS) [1] before new P2Y12 blockers demonstrated their clinical benefit in large randomized controlled trials [2,3]. European guidelines [4] recommended the use of Prasugrel or Ticagrelor in ACS patients as first choice. Prasugrel is the more recent available thienopyridine drug, and Ticagrelor, a direct and reversible P2Y12 blocker, is preferred with a higher level of evidence than Clopidogrel (level B for both versus C).